Identification

Name
Misoprostol
Accession Number
DB00929  (APRD00037, DB05379)
Type
Small Molecule
Groups
Approved
Description

A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties.

Structure
Thumb
Synonyms
  • Misoprostolum
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CytotecTablet200 ug/1OralApotheca, Inc.2010-01-01Not applicableUs
CytotecTablet100 ug/1OralPd Rx Pharmaceuticals, Inc.1986-12-27Not applicableUs
CytotecTablet100 ug/1OralPhysicians Total Care, Inc.1996-07-02Not applicableUs
CytotecTablet100 ug/1OralG.D. Searle LLC Division of Pfizer Inc1986-12-27Not applicableUs
CytotecTablet200 ug/1OralCardinal Health1988-12-27Not applicableUs
CytotecTablet200 ug/1OralA S Medication Solutions1986-12-272017-06-20Us
CytotecTablet200 ug/1OralG.D. Searle LLC Division of Pfizer Inc1986-12-27Not applicableUs
CytotecTablet100 ug/1OralCardinal Health1988-12-27Not applicableUs
Cytotec 100 McgTablet100 mcgOralPfizer1989-12-312004-07-26Canada
Cytotec 200 McgTablet200 mcgOralPfizer1986-12-312005-08-05Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MisoprostolTablet200 ug/1OralKaiser Foundations Hospitals2016-09-20Not applicableUs
MisoprostolTablet100 ug/1OralApotheca, Inc.2010-02-252017-03-04Us
MisoprostolTablet200 ug/1Oralbryant ranch prepack2002-07-10Not applicableUs
MisoprostolTablet200 ug/1OralAvera Mc Kennan Hospital2015-04-06Not applicableUs
MisoprostolTablet200 ug/1OralAmerincan Health Packaging2013-07-01Not applicableUs
MisoprostolTablet100 ug/1OralNovel Laboratories, Inc.2012-07-25Not applicableUs
MisoprostolTablet200 ug/1OralUnit Dose Services2013-04-12Not applicableUs
MisoprostolTablet200 ug/1OralGavis Pharmaceuticals, LLC.2012-07-25Not applicableUs
MisoprostolTablet200 ug/1OralPd Rx Pharmaceuticals, Inc.2012-07-25Not applicableUs
MisoprostolTablet200 ug/1OralAidarex Pharmaceuticals LLC2012-07-25Not applicableUs
International/Other Brands
Isprelor
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Act Diclo-misoMisoprostol (200 mcg) + Diclofenac sodium (50 mg)Tablet, delayed releaseOralActavis Pharma Company2013-03-27Not applicableCanada
Act Diclo-misoMisoprostol (200 mcg) + Diclofenac sodium (75 mg)Tablet, delayed releaseOralActavis Pharma Company2013-03-27Not applicableCanada
ArthrotecMisoprostol (200 ug/1) + Diclofenac sodium (50 mg/1)Tablet, film coatedOralG.D. Searle LLC Division of Pfizer Inc1997-12-24Not applicableUs00025 1411 60 nlmimage10 c812e407
ArthrotecMisoprostol (200 ug/1) + Diclofenac sodium (75 mg/1)Tablet, film coatedOralA S Medication Solutions1997-12-242017-06-20Us
ArthrotecMisoprostol (200 ug/1) + Diclofenac sodium (50 mg/1)Tablet, film coatedOralPhysicians Total Care, Inc.2009-10-07Not applicableUs
ArthrotecMisoprostol (200 ug/1) + Diclofenac sodium (75 mg/1)Tablet, film coatedOralStat Rx USA1997-12-24Not applicableUs
ArthrotecMisoprostol (200 ug/1) + Diclofenac sodium (75 mg/1)Tablet, film coatedOralbryant ranch prepack1997-12-24Not applicableUs
ArthrotecMisoprostol (200 ug/1) + Diclofenac sodium (75 mg/1)Tablet, film coatedOralG.D. Searle LLC Division of Pfizer Inc1997-12-24Not applicableUs00025 1421 60 nlmimage10 ca12e557
ArthrotecMisoprostol (200 ug/1) + Diclofenac sodium (75 mg/1)Tablet, film coatedOralPhysicians Total Care, Inc.2004-12-28Not applicableUs
ArthrotecMisoprostol (200 ug/1) + Diclofenac sodium (50 mg/1)Tablet, film coatedOralPd Rx Pharmaceuticals, Inc.1997-12-24Not applicableUs
Categories
UNII
0E43V0BB57
CAS number
59122-46-2
Weight
Average: 382.5341
Monoisotopic: 382.271924326
Chemical Formula
C22H38O5
InChI Key
OJLOPKGSLYJEMD-URPKTTJQSA-N
InChI
InChI=1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1
IUPAC Name
methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(1E)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate
SMILES
CCCCC(C)(O)C\C=C\[[email protected]]1[[email protected]](O)CC(=O)[[email protected]@H]1CCCCCCC(=O)OC

Pharmacology

Indication

Indicated for the treatment of ulceration (duodenal, gastric and NSAID induced) and prophylaxis for NSAID induced ulceration. Misoprostol is also indicated for other uses that are not approved in Canada, including the medical termination of an intrauterine pregnancy used alone or in combination with methotrexate,as well as the induction of labour in a selected population of pregnant women with unfavourable cervices. This indication is avoided in women with prior uterine surgery or cesarean surgery due to an increased risk of possible uterine rupture. Misoprostol is also used for the prevention or treatment of serious postpartum hemorrhage.

Structured Indications
Pharmacodynamics

Misoprostol is a prostaglandin E1 (PGE1) analogue used for the treatment and prevention of stomach ulcers. When administered, misoprostol stimulates increased secretion of the protective mucus that lines the gastrointestinal tract and increases mucosal blood flow, thereby increasing mucosal integrity. It is sometimes co-prescribed with non-steroidal anti-inflammatory drugs (NSAIDs) to prevent the occurrence of gastric ulceration, a common adverse effect of the NSAIDs.

Mechanism of action

Misoprostol seems to inhibit gastric acid secretion by a direct action on the parietal cells through binding to the prostaglandin receptor. The activity of this receptor is mediated by G proteins which normally activate adenylate cyclase. The indirect inhibition of adenylate cyclase by Misoprostol may be dependent on guanosine-5’-triphosphate (GTP). The significant cytoprotective actions of misoprostol are related to several mechanisms. These include: 1. Increased secretion of bicarbonate, 2. Considerable decrease in the volume and pepsin content of the gastric secretions, 3. It prevents harmful agents from disrupting the tight junctions between the epithelial cells which stops the subsequent back diffusion of H+ ions into the gastric mucosa, 4. Increased thickness of mucus layer, 5. Enhanced mucosal blood flow as a result of direct vasodilatation, 6. Stabilization of tissue lysozymes/vascular endothelium, 7. Improvement of mucosal regeneration capacity, and 8. Replacement of prostaglandins that have been depleted as a result of various insults to the area. Misoprostol has also been shown to increase the amplitude and frequency of uterine contractions during pregnancy via selective binding to the EP-2/EP-3 prostanoid receptors.

TargetActionsOrganism
AProstaglandin E2 receptor EP3 subtype
agonist
Human
AProstaglandin E2 receptor EP2 subtype
agonist
Human
UProstaglandin E2 receptor EP4 subtype
agonist
Human
Absorption

Misoprostol is extensively absorbed.

Volume of distribution
Not Available
Protein binding

85%

Metabolism

Rapidly de-esterified to misoprostol acid. The de-esterified metabolite undergoes further metabolism by beta and omega oxidation; oxidation is followed by reduction of the ketone to yield prostaglandin F analogs.

Route of elimination

After a single oral dose of misoprostol to nursing mothers, misoprostol acid was excreted in breast milk.

Half life

20-40 minutes

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Aceclofenac.Approved
AcemetacinThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Acemetacin.Approved
Acetylsalicylic acidThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Adapalene.Approved
AlclofenacThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlgeldrateThe risk or severity of adverse effects can be increased when Algeldrate is combined with Misoprostol.Experimental
AlmagateThe risk or severity of adverse effects can be increased when Almagate is combined with Misoprostol.Experimental
AlmasilateThe risk or severity of adverse effects can be increased when Almasilate is combined with Misoprostol.Experimental
AlminoprofenThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Alminoprofen.Experimental
AloglutamolThe risk or severity of adverse effects can be increased when Aloglutamol is combined with Misoprostol.Experimental
AluminiumThe risk or severity of adverse effects can be increased when Aluminium is combined with Misoprostol.Approved
Aluminium acetoacetateThe risk or severity of adverse effects can be increased when Aluminium acetoacetate is combined with Misoprostol.Experimental
Aluminium glycinateThe risk or severity of adverse effects can be increased when Aluminium glycinate is combined with Misoprostol.Experimental
Aluminum hydroxideThe risk or severity of adverse effects can be increased when Aluminum hydroxide is combined with Misoprostol.Approved
AndrographolideThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Andrographolide.Investigational
AnisodamineThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Anisodamine.Investigational
AntipyrineThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Antipyrine.Approved
ApocyninThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Apocynin.Investigational
ApremilastThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Apremilast.Approved, Investigational
AzapropazoneThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Azelastine.Approved
BalsalazideThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Balsalazide.Approved, Investigational
BendazacThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Bendazac.Experimental
BenorilateThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Benoxaprofen.Withdrawn
BevoniumThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Bevonium.Experimental
Bismuth SubcitrateThe risk or severity of adverse effects can be increased when Bismuth Subcitrate is combined with Misoprostol.Approved
Bismuth subnitrateThe risk or severity of adverse effects can be increased when Bismuth subnitrate is combined with Misoprostol.Experimental
BromfenacThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Bucillamine.Investigational
BufexamacThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Bufexamac.Experimental
BumadizoneThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Bumadizone.Experimental
Calcium CarbonateThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Misoprostol.Approved
Calcium silicateThe risk or severity of adverse effects can be increased when Calcium silicate is combined with Misoprostol.Experimental
Carbaspirin calciumThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Carbaspirin calcium.Experimental
CarbetocinThe risk or severity of adverse effects can be increased when Misoprostol is combined with Carbetocin.Approved
Carboprost TromethamineThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Misoprostol.Approved
CarprofenThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CastanospermineThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Celecoxib.Approved, Investigational
ChloroquineThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Chloroquine.Approved, Vet Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Choline magnesium trisalicylate.Approved
ClonixinThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Clonixin.Approved
CurcuminThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Curcumin.Investigational
D-LimoneneThe therapeutic efficacy of Misoprostol can be decreased when used in combination with D-Limonene.Investigational
DiclofenacThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DifenpiramideThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Difenpiramide.Experimental
DiflunisalThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Diflunisal.Approved
DroxicamThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Droxicam.Approved
DuvelisibThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Misoprostol can be decreased when used in combination with E-6201.Investigational
EpirizoleThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Epirizole.Approved
EtanerceptThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Etanercept.Approved, Investigational
EthenzamideThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Ethenzamide.Experimental
EtodolacThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Etofenamate.Approved
EtoricoxibThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Etoricoxib.Approved, Investigational
Evening primrose oilThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Evening primrose oil.Approved
exisulindThe therapeutic efficacy of Misoprostol can be decreased when used in combination with exisulind.Investigational
FelbinacThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Felbinac.Experimental
FenbufenThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Fenbufen.Approved
FenoprofenThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Fenoprofen.Approved
FentiazacThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Ferulic acid.Experimental
FloctafenineThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FlunixinThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Flunoxaprofen.Experimental
FlurbiprofenThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Flurbiprofen.Approved, Investigational
GuacetisalThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Guacetisal.Experimental
HigenamineThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Higenamine.Investigational
HydrotalciteThe risk or severity of adverse effects can be increased when Hydrotalcite is combined with Misoprostol.Experimental
IbuprofenThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Icatibant.Approved
Imidazole salicylateThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Imidazole salicylate.Experimental
IndobufenThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Indoprofen.Withdrawn
IsoxicamThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Isoxicam.Withdrawn
KebuzoneThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Kebuzone.Experimental
KetoprofenThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Ketorolac.Approved
LeflunomideThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Leflunomide.Approved, Investigational
LisofyllineThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Lisofylline.Investigational
LonazolacThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Lornoxicam.Approved
LoxoprofenThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MagaldrateThe risk or severity of adverse effects can be increased when Magaldrate is combined with Misoprostol.Withdrawn
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Magnesium Hydroxide is combined with Misoprostol.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Magnesium oxide is combined with Misoprostol.Approved
Magnesium peroxideThe risk or severity of adverse effects can be increased when Magnesium peroxide is combined with Misoprostol.Experimental
Magnesium salicylateThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Magnesium salicylate.Approved
Magnesium silicateThe risk or severity of adverse effects can be increased when Magnesium silicate is combined with Misoprostol.Experimental
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Misoprostol.Approved
MasoprocolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Masoprocol.Approved
Meclofenamic acidThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mefenamic acid.Approved
MeloxicamThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Metamizole.Withdrawn
MizoribineThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mizoribine.Investigational
MofebutazoneThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mofebutazone.Experimental
Mycophenolate mofetilThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Nabumetone.Approved
NafamostatThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Naftifine.Approved
NaproxenThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Naproxen.Approved, Vet Approved
NepafenacThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Nepafenac.Approved
NifenazoneThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Niflumic Acid.Approved
NimesulideThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NitroaspirinThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Nitroaspirin.Investigational
OlopatadineThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Olsalazine.Approved
OrgoteinThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Orgotein.Vet Approved
OxaprozinThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Oxaprozin.Approved
OxyphenbutazoneThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Oxyphenbutazone.Withdrawn
OxytocinThe risk or severity of adverse effects can be increased when Misoprostol is combined with Oxytocin.Approved, Vet Approved
ParecoxibThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Parecoxib.Approved
ParthenolideThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Parthenolide.Investigational
PhenylbutazoneThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PirfenidoneThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Pirfenidone.Investigational
PiroxicamThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Pirprofen.Experimental
PranoprofenThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Pranoprofen.Experimental
ProglumetacinThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Propacetamol.Approved
PropyphenazoneThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Proquazone.Experimental
PTC299The therapeutic efficacy of Misoprostol can be decreased when used in combination with PTC299.Investigational
ResveratrolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Resveratrol.Experimental, Investigational
RofecoxibThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
SalicylamideThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalsalateThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Salsalate.Approved
SemapimodThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Serrapeptase.Investigational
SRT501The therapeutic efficacy of Misoprostol can be decreased when used in combination with SRT501.Investigational
SulfasalazineThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Sulindac.Approved
SuprofenThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Suxibuzone.Experimental
TarenflurbilThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tarenflurbil.Investigational
TenidapThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tepoxalin.Vet Approved
TeriflunomideThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Teriflunomide.Approved
Tiaprofenic acidThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tiaprofenic acid.Approved
TinoridineThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tinoridine.Investigational
Tolfenamic AcidThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tolmetin.Approved
TranilastThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tranilast.Approved, Investigational
TribenosideThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tribenoside.Experimental
TriptolideThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Triptolide.Investigational
ValdecoxibThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ZaltoprofenThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
  • Take with food to decrease the incidence of diarrhea.

References

Synthesis Reference

Salah Ahmed, Raj Mahajan, "Vaginal tablets comprising misoprostol and methods of making and using the same." U.S. Patent US20070071814, issued March 29, 2007.

US20070071814
General References
  1. Costa SH, Vessey MP: Misoprostol and illegal abortion in Rio de Janeiro, Brazil. Lancet. 1993 May 15;341(8855):1258-61. [PubMed:8098402]
  2. Coelho HL, Teixeira AC, Cruz Mde F, Gonzaga SL, Arrais PS, Luchini L, La Vecchia C, Tognoni G: Misoprostol: the experience of women in Fortaleza, Brazil. Contraception. 1994 Feb;49(2):101-10. [PubMed:8143449]
  3. Barbosa RM, Arilha M: The Brazilian experience with Cytotec. Stud Fam Plann. 1993 Jul-Aug;24(4):236-40. [PubMed:8212093]
  4. Rocha J: Brazil investigates drug's possible link with birth defects. BMJ. 1994 Sep 24;309(6957):757-8. [PubMed:7950553]
  5. Gonzalez CH, Vargas FR, Perez AB, Kim CA, Brunoni D, Marques-Dias MJ, Leone CR, Correa Neto J, Llerena Junior JC, de Almeida JC: Limb deficiency with or without Mobius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. Am J Med Genet. 1993 Aug 1;47(1):59-64. [PubMed:8368254]
External Links
Human Metabolome Database
HMDB15064
KEGG Drug
D00419
PubChem Compound
5282381
PubChem Substance
46505041
ChemSpider
4445541
BindingDB
85606
ChEBI
63610
ChEMBL
CHEMBL606
Therapeutic Targets Database
DAP000358
PharmGKB
PA450523
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Misoprostol
ATC Codes
G02AD06 — MisoprostolM01AE56 — Naproxen and misoprostolA02BB01 — Misoprostol
AHFS Codes
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
  • 76:00.00 — Oxytocics
  • 56:28.28 — Prostaglandins
FDA label
Download (246 KB)
MSDS
Download (147 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceGYNAECOLOGICAL INFECTION1
0Not Yet RecruitingPreventionPrimary Postpartum Haemorrhage1
1CompletedBasic ScienceHypotonic; Labor1
1CompletedPreventionPain Prior to IUD Insertion1
1CompletedPreventionPost Partum Hemorrhage1
1CompletedTreatmentArrest of Dilation in Labor1
1CompletedTreatmentIncomplete Abortion1
1CompletedTreatmentInduction of Labour1
1CompletedTreatmentPlacenta, Retained1
1TerminatedTreatmentSecond Trimester Labor Induction1
1, 2CompletedPreventionPost Partum Haemorrhage1
1, 2Unknown StatusTreatmentFetal Demise / Fetal Membranes, Premature Rupture / Preeclampsia1
2CompletedPreventionCesarean Delivery / Pregnancy1
2CompletedPreventionPostpartum Hemorrhage2
2CompletedTreatmentAbortion, Therapeutic1
2CompletedTreatmentCervical Priming1
2CompletedTreatmentCervical Ripening / Premature Births1
2CompletedTreatmentDelivery Uterine1
2CompletedTreatmentFirst Trimester Pregnancy / Surgical Termination of Pregnancy1
2CompletedTreatmentInduction of Labor Affected Fetus / Newborn1
2CompletedTreatmentInduction of Labour1
2CompletedTreatmentMissed Abortion1
2CompletedTreatmentPain1
2CompletedTreatmentPregnancy Termination1
2Not Yet RecruitingTreatmentLabor; Forced or Induced, Affecting Fetus or Newborn1
2RecruitingNot AvailableInduction of Labour1
2RecruitingTreatmentCervical Ripening1
2RecruitingTreatmentLate Second Trimester Termination of Pregnancy1
2RecruitingTreatmentMissed Abortion1
2RecruitingTreatmentPain1
2RecruitingTreatmentPlacenta, Retained / Postpartum Hemorrhage1
2RecruitingTreatmentPostpartum Hemorrhage1
2RecruitingTreatmentInduction of Uterine contractions1
2TerminatedTreatmentIntra-uterine Residua1
2Unknown StatusNot AvailablePregnancy Termination1
2, 3CompletedNot AvailableIUD Insertion1
2, 3CompletedPreventionCesarean Section1
2, 3CompletedPreventionPostpartum Hemorrhage2
2, 3CompletedTreatmentAbortions spontaneous1
2, 3CompletedTreatmentComplete Miscarriage1
2, 3CompletedTreatmentFailed Induction of Labor1
2, 3CompletedTreatmentPregnancy1
2, 3CompletedTreatmentTermed Pregnancy With Indications for Labor Induction1
2, 3RecruitingDiagnosticUlcer Hemorrhage1
2, 3RecruitingPreventionNeonatal Outcome1
2, 3SuspendedTreatmentMissed Abortion1
2, 3Unknown StatusPreventionBleeding Intraoperative1
2, 3Unknown StatusTreatmentSpontaneous Abortion in First Trimester1
3Active Not RecruitingTreatmentPostpartum Hemorrhage1
3Active Not RecruitingTreatmentSpontaneous Abortions1
3CompletedNot AvailableCervical Ripening1
3CompletedNot AvailableLabour Pain1
3CompletedHealth Services ResearchInduction of Uterine contractions1
3CompletedPreventionAbortifacient Agents, Nonsteroidal / Incomplete Abortion / Misoprostol / Pregnancy1
3CompletedPreventionAnkylosing Spondylitis (AS) / Rheumatoid Arthritis / Synovitis of osteoarthritis1
3CompletedPreventionComplications; Cesarean Section1
3CompletedPreventionLeiomyomas1
3CompletedPreventionPostpartum Hemorrhage2
3CompletedPreventionSevere Pre-eclampsia, Postpartum Condition or Complication1
3CompletedTreatmentAbnormal Uterine and Vaginal Bleeding, Unspecified / Infertilities / Recurrent Abortion1
3CompletedTreatmentCervical Ripening1
3CompletedTreatmentEndometrial Biopsy1
3CompletedTreatmentEndometrial Disorder1
3CompletedTreatmentFailed Induction of Labor1
3CompletedTreatmentFetus or Newborn; Effects of Induction of Labor / Prophylaxis of preeclampsia1
3CompletedTreatmentInduction of Labour2
3CompletedTreatmentIntrauterine Fetal Demise1
3CompletedTreatmentMedical Abortion1
3CompletedTreatmentPost Partum Hemorrhage1
3CompletedTreatmentPostpartum Hemorrhage1
3CompletedTreatmentPregnancy1
3CompletedTreatmentPregnancy Termination1
3CompletedTreatmentUterine Hemorrhage1
3Not Yet RecruitingPreventionPost Partum Hemorrhage1
3RecruitingDiagnosticPregnancy1
3RecruitingTreatmentAnemias / Chronic Arthritis / Haemorrhage / Ischaemic Heart Diseases / Nonvalvular Atrial Fibrillation1
3RecruitingTreatmentFetal Demise1
3RecruitingTreatmentMedical; Abortion, Fetus1
3TerminatedPreventionBlood Loss / Pregnancy termination therapy1
3TerminatedTreatmentGastric Ulcer (GU)1
3TerminatedTreatmentInduction of Labour1
3TerminatedTreatmentPregnancy Termination1
3TerminatedTreatmentInduction of Uterine contractions1
3Unknown StatusPreventionBlood Loss1
3Unknown StatusTreatmentCervical Ripening1
3Unknown StatusTreatmentMedical Abortion1
3Unknown StatusTreatmentMedical Induction of Labor Affecting Fetus1
3WithdrawnPreventionPostpartum Hemorrhage1
3WithdrawnTreatmentCervical Ripening / Endometrial Biopsy / Hypermenorrhea1
4CompletedHealth Services ResearchMenstrual Regulation1
4CompletedPreventionHemorrhage1
4CompletedPreventionNSAID-associated Gastroduodenal Injury1
4CompletedPreventionPostpartum Hemorrhage2
4CompletedPreventionPostpartum Hemorrhage / Intrapartum Haemorrhage1
4CompletedPreventionProstaglandin E2 "Misoprostol" Prior Abdominal Myomectomy / Prostaglandin E2 Misoprostol Prior Abdominal Myomectomy1
4CompletedTreatmentAbortion Seekers1
4CompletedTreatmentAbortion, 3 Months1
4CompletedTreatmentAbortion, Legal1
4CompletedTreatmentAnembryonic Pregnancy / Gestation Abnormality / Intrauterine Fetal Demise Term1
4CompletedTreatmentCervical Ripening / Induction of Uterine contractions1
4CompletedTreatmentCervical Stenosis1
4CompletedTreatmentComplete Uterine Evacuation After Use of Study Drugs1
4CompletedTreatmentComplications, Pregnancy1
4CompletedTreatmentContraception / Hypermenorrhea1
4CompletedTreatmentInduction of Labour / Pregnancy1
4CompletedTreatmentLabor Augmentation1
4CompletedTreatmentMaternal Care for Late Fetal Death / Pregnancy, Cornual1
4CompletedTreatmentMedical Abortion2
4CompletedTreatmentMissed Abortion1
4CompletedTreatmentPregnancy Termination2
4CompletedTreatmentPregnancy Termination / Pregnancy Trimester, Second1
4CompletedTreatmentPremature Rupture of Membranes at Term2
4CompletedTreatmentSecond Trimester Abortions1
4CompletedTreatmentUnwanted Pregnancies1
4Not Yet RecruitingHealth Services ResearchPostpartum Hemorrhage1
4Not Yet RecruitingTreatmentEarly Pregnancy Failure1
4Not Yet RecruitingTreatmentMedical Abortion1
4Not Yet RecruitingTreatmentMisoprostol, Blood Loss, Myomectomy1
4RecruitingHealth Services ResearchAbortion, Therapeutic1
4RecruitingOtherContraceptive Device; Complications1
4RecruitingPreventionCervical Preparation Prior to Hysteroscopy1
4RecruitingPreventionMyomectomy; Surgical Blood Loss1
4RecruitingPreventionPostpartum Hemorrhage2
4RecruitingPreventionPregnancy Termination1
4RecruitingPreventionVaginal Misoprostol and Bilateral Uterine Artery Ligation in Decreasing Blood Loss in Trans-abdominal Myomectomy1
4RecruitingTreatmentAbortion Failure1
4RecruitingTreatmentBMI >30 kg/m2 / Cesarean Delivery / Induction of Uterine contractions1
4RecruitingTreatmentCatheters / Misoprostol / Pregnancy Trimester, Second / Second Trimester Abortions1
4RecruitingTreatmentCervical Ripening / Induction of Labour / Pregnancy1
4RecruitingTreatmentInduced Deliveries1
4RecruitingTreatmentInduction of Labour1
4RecruitingTreatmentLabor; Forced or Induced, Affecting Fetus or Newborn / Pregnancy1
4RecruitingTreatmentLegally Induced Abortion Without Mention of Complication1
4RecruitingTreatmentLeiomyomas1
4RecruitingTreatmentMiscarriage, Incomplete1
4RecruitingTreatmentMissed Abortion / Pregnancy1
4RecruitingTreatmentPostpartum Hemorrhage1
4RecruitingTreatmentSecond Trimester Abortions1
4RecruitingTreatmentInduction of Uterine contractions1
4TerminatedPreventionHemorrhage; Complicating Delivery1
4TerminatedTreatmentPregnancy1
4Unknown StatusTreatmentCervical Ripening1
4Unknown StatusTreatmentInduced / Labour1
4Unknown StatusTreatmentLabour1
4Unknown StatusTreatmentPregnancy Termination / Spontaneous Abortions1
Not AvailableActive Not RecruitingTreatmentLegally Induced Abortion Without Mention of Complication1
Not AvailableActive Not RecruitingTreatmentSpinal Stenosis of Lumbar Region1
Not AvailableActive Not RecruitingTreatmentSpontaneous Abortions1
Not AvailableCompletedNot AvailableBMI >30 kg/m2 / Induced; Birth1
Not AvailableCompletedNot AvailableCervical Ripening1
Not AvailableCompletedNot AvailableComplete Abortion1
Not AvailableCompletedNot AvailableInduction of Labour1
Not AvailableCompletedHealth Services ResearchContraception1
Not AvailableCompletedHealth Services ResearchNeonatal Asphyxia / Postpartum Hemorrhage1
Not AvailableCompletedHealth Services ResearchPostpartum Hemorrhage1
Not AvailableCompletedHealth Services ResearchPregnancy Termination1
Not AvailableCompletedPreventionAnemias / Postpartum Hemorrhage1
Not AvailableCompletedPreventionPlacenta, Retained / Postpartum Hemorrhage1
Not AvailableCompletedPreventionPostpartum Hemorrhage3
Not AvailableCompletedPreventionPostpartum Hemorrhage / Pregnancy1
Not AvailableCompletedSupportive CareContraception1
Not AvailableCompletedTreatmentContraception2
Not AvailableCompletedTreatmentHysterectomy1
Not AvailableCompletedTreatmentIncomplete Abortion4
Not AvailableCompletedTreatmentInduced; Abortion, Nonmedical1
Not AvailableCompletedTreatmentInduction of Labour2
Not AvailableCompletedTreatmentLabor Induction at Term1
Not AvailableCompletedTreatmentLegally Induced Abortion Without Mention of Complication1
Not AvailableCompletedTreatmentOligohydramnios / Pre Eclampsia / Prolonged Pregnancy1
Not AvailableCompletedTreatmentPain1
Not AvailableCompletedTreatmentPain During Hysteroscopy1
Not AvailableCompletedTreatmentPostpartum Hemorrhage5
Not AvailableCompletedTreatmentPostpartum Hemorrhage (PPH)1
Not AvailableCompletedTreatmentPregnancy1
Not AvailableCompletedTreatmentPregnancy Termination9
Not AvailableCompletedTreatmentTermination1
Not AvailableCompletedTreatmentTermination of Pregnancy Second Trimester1
Not AvailableNot Yet RecruitingDiagnosticPregnancies of Unknown Location (PUL)1
Not AvailableNot Yet RecruitingTreatmentIncomplete Abortion1
Not AvailableRecruitingPreventionCesarean Delivery Affecting Fetus / Transient Tachypnea Newborn1
Not AvailableRecruitingPreventionMaternal Infection During Pregnancy (Diagnosis) / Neonatal Infections1
Not AvailableRecruitingPreventionNeonatal Respiratory Distress1
Not AvailableRecruitingPreventionPregnancy / Premature Rupture of Membranes / Preterm Premature Rupture of Membranes1
Not AvailableRecruitingTreatmentCervical Ripening1
Not AvailableRecruitingTreatmentIUD Insertion Complication1
Not AvailableRecruitingTreatmentMissed Abortion1
Not AvailableRecruitingTreatmentPostpartum Hemorrhage1
Not AvailableRecruitingTreatmentInduction of Uterine contractions1
Not AvailableTerminatedTreatmentAbortion, Therapeutic / Pregnancy Trimester, Second1
Not AvailableTerminatedTreatmentAbortions spontaneous / Anembryonic Pregnancy / Early Pregnancy Failure / Fetal Demise1
Not AvailableTerminatedTreatmentContraception1
Not AvailableTerminatedTreatmentDiabetes, Gestational1
Not AvailableTerminatedTreatmentPregnancy1
Not AvailableTerminatedTreatmentStenosis of Cervix1
Not AvailableUnknown StatusNot AvailableInduction of Uterine contractions1
Not AvailableUnknown StatusHealth Services ResearchOther Abortion1
Not AvailableUnknown StatusTreatmentAbnormal Uterine Bleeding Unrelated to Menstrual Cycle1
Not AvailableUnknown StatusTreatmentAbortion Techniques / Mifepristone / Misoprostol / Pregnancy Termination1
Not AvailableUnknown StatusTreatmentComplete Abortion1
Not AvailableUnknown StatusTreatmentInduction of Labor in Multiparous Women1
Not AvailableWithdrawnPreventionPostpartum Hemorrhage1

Pharmacoeconomics

Manufacturers
  • Gd searle llc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedOral
TabletOral200 ug/1
Tablet, delayed releaseOral
Kit; tabletBuccal; Oral
TabletOral100 mcg
TabletOral100 ug/1
TabletOral200 mcg
TabletOral0.1 mg
TabletOral0.2 mg
TabletOral
Prices
Unit descriptionCostUnit
Misoprostol hpmc powder152.0USD g
Cytotec 60 200 mcg tablet Bottle121.93USD bottle
Cytotec 60 100 mcg tablet Bottle81.36USD bottle
Arthrotec 75 tablet ec4.07USD tablet
Arthrotec ec 50 mg-200 mcg tablet2.99USD tablet
Arthrotec ec 75 mg-200 mcg tablet2.99USD tablet
Arthrotec ec 75 tablet2.96USD tablet
Arthrotec 75 75-200 mg-mcg tablet2.82USD tablet
Arthrotec 50 50-200 mg-mcg tablet2.7USD tablet
Cytotec 200 mcg tablet1.95USD tablet
Cytotec 100 mcg tablet1.34USD tablet
Misoprostol 200 mcg tablet1.22USD tablet
Misoprostol 100 mcg tablet0.84USD tablet
Apo-Misoprostol 200 mcg Tablet0.45USD tablet
Apo-Misoprostol 100 mcg Tablet0.27USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5601843No1994-02-112014-02-11Us
US5698225No1993-05-032010-05-03Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
water solubility>1.6 mg/mL at 25.0 °CNot Available
logP3.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0164 mg/mLALOGPS
logP3.88ALOGPS
logP3.86ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)14.68ChemAxon
pKa (Strongest Basic)-0.95ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area83.83 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity107.88 m3·mol-1ChemAxon
Polarizability45.38 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9157
Blood Brain Barrier+0.938
Caco-2 permeable-0.5339
P-glycoprotein substrateSubstrate0.6607
P-glycoprotein inhibitor INon-inhibitor0.7261
P-glycoprotein inhibitor IIInhibitor0.6504
Renal organic cation transporterNon-inhibitor0.9146
CYP450 2C9 substrateNon-substrate0.857
CYP450 2D6 substrateNon-substrate0.9024
CYP450 3A4 substrateSubstrate0.6281
CYP450 1A2 substrateNon-inhibitor0.8358
CYP450 2C9 inhibitorNon-inhibitor0.8175
CYP450 2D6 inhibitorNon-inhibitor0.9459
CYP450 2C19 inhibitorNon-inhibitor0.8199
CYP450 3A4 inhibitorNon-inhibitor0.795
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9591
Ames testNon AMES toxic0.8289
CarcinogenicityNon-carcinogens0.8941
BiodegradationNot ready biodegradable0.8797
Rat acute toxicity3.7051 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.964
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Eicosanoids
Direct Parent
Prostaglandins and related compounds
Alternative Parents
Fatty acid methyl esters / Cyclopentanols / Tertiary alcohols / Methyl esters / Cyclic ketones / Cyclic alcohols and derivatives / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Prostaglandin skeleton / Fatty acid ester / Fatty acid methyl ester / Cyclopentanol / Cyclic alcohol / Tertiary alcohol / Methyl ester / Secondary alcohol / Ketone / Carboxylic acid ester
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Rna polymerase ii transcription factor activity, ligand-activated sequence-specific dna binding
Specific Function
Receptor for prostaglandin E2 (PGE2); the EP3 receptor may be involved in inhibition of gastric acid secretion, modulation of neurotransmitter release in central and peripheral neurons, inhibition ...
Gene Name
PTGER3
Uniprot ID
P43115
Uniprot Name
Prostaglandin E2 receptor EP3 subtype
Molecular Weight
43309.335 Da
References
  1. Nakae K, Hayashi F, Hayashi M, Yamamoto N, Iino T, Yoshikawa S, Gupta J: Functional role of prostacyclin receptor in rat dorsal root ganglion neurons. Neurosci Lett. 2005 Nov 18;388(3):132-7. [PubMed:16039053]
  2. Li J, Liang X, Wang Q, Breyer RM, McCullough L, Andreasson K: Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci Lett. 2008 Jun 20;438(2):210-5. doi: 10.1016/j.neulet.2008.04.054. Epub 2008 Apr 20. [PubMed:18472336]
  3. Guan Y, Stillman BA, Zhang Y, Schneider A, Saito O, Davis LS, Redha R, Breyer RM, Breyer MD: Cloning and expression of the rabbit prostaglandin EP2 receptor. BMC Pharmacol. 2002 Jun 27;2:14. [PubMed:12097143]
  4. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S: Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. [PubMed:9313928]
  5. Nataraj C, Thomas DW, Tilley SL, Nguyen MT, Mannon R, Koller BH, Coffman TM: Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest. 2001 Oct;108(8):1229-35. [PubMed:11602631]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Prostaglandin e receptor activity
Specific Function
Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. The subsequent raise in intracellular cAMP is responsible for the ...
Gene Name
PTGER2
Uniprot ID
P43116
Uniprot Name
Prostaglandin E2 receptor EP2 subtype
Molecular Weight
39759.945 Da
References
  1. Nakae K, Hayashi F, Hayashi M, Yamamoto N, Iino T, Yoshikawa S, Gupta J: Functional role of prostacyclin receptor in rat dorsal root ganglion neurons. Neurosci Lett. 2005 Nov 18;388(3):132-7. [PubMed:16039053]
  2. Li J, Liang X, Wang Q, Breyer RM, McCullough L, Andreasson K: Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci Lett. 2008 Jun 20;438(2):210-5. doi: 10.1016/j.neulet.2008.04.054. Epub 2008 Apr 20. [PubMed:18472336]
  3. Guan Y, Stillman BA, Zhang Y, Schneider A, Saito O, Davis LS, Redha R, Breyer RM, Breyer MD: Cloning and expression of the rabbit prostaglandin EP2 receptor. BMC Pharmacol. 2002 Jun 27;2:14. [PubMed:12097143]
  4. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S: Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. [PubMed:9313928]
  5. Nataraj C, Thomas DW, Tilley SL, Nguyen MT, Mannon R, Koller BH, Coffman TM: Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest. 2001 Oct;108(8):1229-35. [PubMed:11602631]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Prostaglandin e receptor activity
Specific Function
Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. Has a relaxing effect on smooth muscle. May play an important role...
Gene Name
PTGER4
Uniprot ID
P35408
Uniprot Name
Prostaglandin E2 receptor EP4 subtype
Molecular Weight
53118.845 Da
References
  1. Nakae K, Hayashi F, Hayashi M, Yamamoto N, Iino T, Yoshikawa S, Gupta J: Functional role of prostacyclin receptor in rat dorsal root ganglion neurons. Neurosci Lett. 2005 Nov 18;388(3):132-7. [PubMed:16039053]
  2. Li J, Liang X, Wang Q, Breyer RM, McCullough L, Andreasson K: Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci Lett. 2008 Jun 20;438(2):210-5. doi: 10.1016/j.neulet.2008.04.054. Epub 2008 Apr 20. [PubMed:18472336]
  3. Guan Y, Stillman BA, Zhang Y, Schneider A, Saito O, Davis LS, Redha R, Breyer RM, Breyer MD: Cloning and expression of the rabbit prostaglandin EP2 receptor. BMC Pharmacol. 2002 Jun 27;2:14. [PubMed:12097143]
  4. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S: Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. [PubMed:9313928]
  5. Nataraj C, Thomas DW, Tilley SL, Nguyen MT, Mannon R, Koller BH, Coffman TM: Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest. 2001 Oct;108(8):1229-35. [PubMed:11602631]
  6. Crider JY, Xu SX, Sharif NA: Pharmacology of functional endogenous IP prostanoid receptors in NCB-20 cells: comparison with binding data from human platelets. Prostaglandins Leukot Essent Fatty Acids. 2001 Nov-Dec;65(5-6):253-8. [PubMed:11993717]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 09:34